B Cells--Tumors clinical trials at UC Davis

1 research study open to eligible people

STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
open to eligible people ages 18 years and up
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
Sacramento, California and other locations

Last updated: June 10, 2024